The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats

Psychopharmacology

Volumn 165, Issue 1, 2002, Pages 86-92

  McElroy, John F ^a   Ward, Kathryn A ^a   Zeller, Kim L ^a   Jones, Keith W ^a   Gilligan, Paul J ^a   He, Liqi ^a   Lelas, Snjezana ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anxiety; Ataxia; Chlordiazepoxide; Corticosterone; CRF1 antagonist; Locomotor activity

Indexed keywords

8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CHLORDIAZEPOXIDE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; ATAXIA; BRAIN LEVEL; CONTROLLED STUDY; DARKNESS; DEFENSIVE BEHAVIOR; DOSE RESPONSE; DRUG MEGADOSE; DRUG SELECTIVITY; ENVIRONMENTAL EXPOSURE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LATENT PERIOD; LOCOMOTION; MALE; MOTOR COORDINATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; STRESS; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; WITHDRAWAL REFLEX;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ATAXIA; BEHAVIOR, ANIMAL; CHLORDIAZEPOXIDE; CONSCIOUS SEDATION; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MOTOR ACTIVITY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS; TRIAZINES;

EID: 0036941164     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1239-3     Document Type: Article

References (32)

1. Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794-803
2. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ (2000) Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: Behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597
3. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629
4. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB (1996) Corticotrophin-releasing factor receptors: From molecular biology to drug design. Trends Pharmacol Sci 17:166-172
5. Costa E, Guidotti A (1996) Benzodiazepines on trial: A research strategy for their rehabilitation. Trends Pharmacol Sci 17:192-200
6. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW (1999) The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140:79-86
7. Griebel G, Perrault G, Sanger DJ (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: Comparison with diazepam and buspirone. Psychopharmacology 138:55-66
8. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084
9. 1 receptor antagonist. J Med Chem 43:449-456
10. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H (2000) Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33:189-193
11. Hill G, Zaczek R, Li Y-W (2001) Corticotropin releasing factor type-1 receptor occupancy of DMP696 in rat brain: Ex vivo binding autoradiography. Soc Neurosci Abstr 27:149.14
12. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council (1996) Guide for the Care and Use of Laboratory Animals, 7th Edn. National Academy Press, Washington, DC
13. Jezova D, Ochedalski T, Glickman M, Kiss A, Aguilera G (1999) Central corticotropin-releasing hormone receptors modulate hypothalamic-pituitary-adrenocortical and sympathoadrenal activity during stress. Neuroscience 94:797-802
14. Jolkkonen J, Lepola U, Bissette G, Nemeroff C, Riekkinen P (1993) CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 33:136-138
15. Kaye WH, Gwirtsman HE, George DT, Ebert MH, Jimerson DC, Tomai TP, Chrousos GP, Gold PW (1987) Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: Relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab 64:203-208
16. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373-380
17. 1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357-1367
18. Kirk RE (1968) Experimental Design: Procedures for the Behavioral Sciences. Brooks/Cole, Belmont, Calif
19. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau J-L (1996) A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309:195-200
20. McElroy JF, Miller JM, Meyer JS (1987) Comparison of the effects of chlordiazepoxide and CL 218,872 on serum corticosterone concentrations in rats. Psychopharmacology 91:467-472
21. Moldow RL, Fischman AJ (1982) Physiological changes in rat hypothalamic CRF: Circadian, stress and steroid suppression. Peptides 3:837-840
22. Pournajafi Nazarloo H, Takao T, Nanmiya W, Asaba K, De Souza EB, Hashimoto K (2001) Effect of non-peptide corticotropin-releasing factor receptor type 1 antagonist in adrenocorticotropic hormone release and interleukin-1 receptors followed by stress. Brain Res 902:119-126
23. Roy A, DeLong J, Gold P, Rubinow D, Adinoff B, Ravitz B, Waxman R, Linnoila M (1990) Cerebrospinal fluid levels of somatostatin, corticotropin-releasing hormone and corticotropin in alcoholism. Acta Psychiatr Scand 82:44-48
24. Sato T, Sato M, Shinsako J, Dallman MF (1975) Corticosterone-induced changes in hypothalamic corticotropin-releasing factor (CRF) content after stress. Endocrinology 97:265-274
25. Stenzel-Poore MP, Duncan JE, Rittenberg MB, Bakke AC, Heinrichs SC (1996) CRH overproduction in transgenic mice: Behavioral and immune system modulation. Ann N Y Acad Sci 780:36-48
26. 2 receptors in fear and anxiety. Neurosci Biobehav Rev 25:627-636
27. Takahashi LK, Kalin NH, Vanden Burgt JA, Sherman JE (1989) Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci 103:648-654
28. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nature Genet 19:162-166
29. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:1394-1397
30. Vale W, Rivier C, Brown MR, Spiess J, Koob G, Swanson L, Bilezikjian L, Bloom F, Rivier J (1983) Chemical and biological characterization of corticotropin-releasing factor. Recent Prog Horm Res 39:245-270
31. Yang XM, Gorman AL, Dunn AJ (1990) The involvement of central noradrenergic systems and corticotropin releasing factor in defensive withdrawal behavior in rats. J Pharmacol Exp Ther 255:1064-1070
32. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 34:171-181